183 related articles for article (PubMed ID: 36923707)
21. The expression of S100A8 in pancreatic cancer-associated monocytes is associated with the Smad4 status of pancreatic cancer cells.
Sheikh AA; Vimalachandran D; Thompson CC; Jenkins RE; Nedjadi T; Shekouh A; Campbell F; Dodson A; Prime W; Crnogorac-Jurcevic T; Lemoine NR; Costello E
Proteomics; 2007 Jun; 7(11):1929-40. PubMed ID: 17469085
[TBL] [Abstract][Full Text] [Related]
22. S100A8 and S100A9 are associated with colorectal carcinoma progression and contribute to colorectal carcinoma cell survival and migration via Wnt/β-catenin pathway.
Duan L; Wu R; Ye L; Wang H; Yang X; Zhang Y; Chen X; Zuo G; Zhang Y; Weng Y; Luo J; Tang M; Shi Q; He T; Zhou L
PLoS One; 2013; 8(4):e62092. PubMed ID: 23637971
[TBL] [Abstract][Full Text] [Related]
23. S100A8 and S100A9, both transcriptionally regulated by PU.1, promote epithelial-mesenchymal transformation (EMT) and invasive growth of dermal keratinocytes during scar formation post burn.
Xu Z; Cheng C; Kong R; Liu Y; Wang S; Ma Y; Xing X
Aging (Albany NY); 2021 Jun; 13(11):15523-15537. PubMed ID: 34099591
[TBL] [Abstract][Full Text] [Related]
24. In neonates S100A8/S100A9 alarmins prevent the expansion of a specific inflammatory monocyte population promoting septic shock.
Heinemann AS; Pirr S; Fehlhaber B; Mellinger L; Burgmann J; Busse M; Ginzel M; Friesenhagen J; von Köckritz-Blickwede M; Ulas T; von Kaisenberg CS; Roth J; Vogl T; Viemann D
FASEB J; 2017 Mar; 31(3):1153-1164. PubMed ID: 27993995
[TBL] [Abstract][Full Text] [Related]
25. Alarmins S100A8 and S100A9 elicit a catabolic effect in human osteoarthritic chondrocytes that is dependent on Toll-like receptor 4.
Schelbergen RF; Blom AB; van den Bosch MH; Slöetjes A; Abdollahi-Roodsaz S; Schreurs BW; Mort JS; Vogl T; Roth J; van den Berg WB; van Lent PL
Arthritis Rheum; 2012 May; 64(5):1477-87. PubMed ID: 22127564
[TBL] [Abstract][Full Text] [Related]
26. Roles of calcium-binding proteins, S100A8 and S100A9, in invasive phenotype of human gastric cancer cells.
Yong HY; Moon A
Arch Pharm Res; 2007 Jan; 30(1):75-81. PubMed ID: 17328245
[TBL] [Abstract][Full Text] [Related]
27. Molecular interface of S100A8 with cytochrome b558 and NADPH oxidase activation.
Berthier S; Nguyen MV; Baillet A; Hograindleur MA; Paclet MH; Polack B; Morel F
PLoS One; 2012; 7(7):e40277. PubMed ID: 22808130
[TBL] [Abstract][Full Text] [Related]
28. S100A8 and S100A9 in inflammation and cancer.
Gebhardt C; Németh J; Angel P; Hess J
Biochem Pharmacol; 2006 Nov; 72(11):1622-31. PubMed ID: 16846592
[TBL] [Abstract][Full Text] [Related]
29. S100A9 Increases IL-6 and RANKL Expressions through MAPKs and STAT3 Signaling Pathways in Osteocyte-Like Cells.
Takagi R; Sakamoto E; Kido JI; Inagaki Y; Hiroshima Y; Naruishi K; Yumoto H
Biomed Res Int; 2020; 2020():7149408. PubMed ID: 32149126
[TBL] [Abstract][Full Text] [Related]
30. Blockade of S100A8 and S100A9 suppresses neutrophil migration in response to lipopolysaccharide.
Vandal K; Rouleau P; Boivin A; Ryckman C; Talbot M; Tessier PA
J Immunol; 2003 Sep; 171(5):2602-9. PubMed ID: 12928412
[TBL] [Abstract][Full Text] [Related]
31. The roles of toll-like receptor 4, CD33, CD68, CD69, or CD147/EMMPRIN for monocyte activation by the DAMP S100A8/S100A9.
Möller A; Jauch-Speer SL; Gandhi S; Vogl T; Roth J; Fehler O
Front Immunol; 2023; 14():1110185. PubMed ID: 37056775
[TBL] [Abstract][Full Text] [Related]
32. S100A8 and S100A9 are messengers in the crosstalk between epidermis and dermis modulating a psoriatic milieu in human skin.
Lee Y; Jang S; Min JK; Lee K; Sohn KC; Lim JS; Im M; Lee HE; Seo YJ; Kim CD; Lee JH
Biochem Biophys Res Commun; 2012 Jul; 423(4):647-53. PubMed ID: 22683330
[TBL] [Abstract][Full Text] [Related]
33. The expression of S100A8/S100A9 is inducible and regulated by the Hippo/YAP pathway in squamous cell carcinomas.
Li Y; Kong F; Jin C; Hu E; Shao Q; Liu J; He D; Xiao X
BMC Cancer; 2019 Jun; 19(1):597. PubMed ID: 31208368
[TBL] [Abstract][Full Text] [Related]
34. Influences of S100A8 and S100A9 on Proliferation of Nasopharyngeal Carcinoma Cells through PI3K/Akt Signaling Pathway.
Wen L; Ding Y; Chen X; Tian K; Li D; Liang K; Yue B
Biomed Res Int; 2021; 2021():9917365. PubMed ID: 34604387
[TBL] [Abstract][Full Text] [Related]
35. Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9.
Schneider RK; Schenone M; Ferreira MV; Kramann R; Joyce CE; Hartigan C; Beier F; Brümmendorf TH; Germing U; Platzbecker U; Büsche G; Knüchel R; Chen MC; Waters CS; Chen E; Chu LP; Novina CD; Lindsley RC; Carr SA; Ebert BL
Nat Med; 2016 Mar; 22(3):288-97. PubMed ID: 26878232
[TBL] [Abstract][Full Text] [Related]
36. Aggregation of human S100A8 and S100A9 amyloidogenic proteins perturbs proteostasis in a yeast model.
Eremenko E; Ben-Zvi A; Morozova-Roche LA; Raveh D
PLoS One; 2013; 8(3):e58218. PubMed ID: 23483999
[TBL] [Abstract][Full Text] [Related]
37. Autocrine pathways involving S100A8 and/or S100A9 that are postulated to regulate the immunological functions of macrophages in rats.
Okada K; Arai S; Nakase H; Kohno H; Nakamura F; Takeda M; Toda Y; Itoh H; Adachi S; Ikemoto M
Biochem Biophys Res Commun; 2015 Jan; 456(1):415-20. PubMed ID: 25485702
[TBL] [Abstract][Full Text] [Related]
38. S100A8/S100A9 deficiency increases neutrophil activation and protective immune responses against invading infective L3 larvae of the filarial nematode Litomosoides sigmodontis.
Frohberger SJ; Fercoq F; Neumann AL; Surendar J; Stamminger W; Ehrens A; Karunakaran I; Remion E; Vogl T; Hoerauf A; Martin C; Hübner MP
PLoS Negl Trop Dis; 2020 Feb; 14(2):e0008119. PubMed ID: 32107497
[TBL] [Abstract][Full Text] [Related]
39. S100A8 and S100A9 mediate endotoxin-induced cardiomyocyte dysfunction via the receptor for advanced glycation end products.
Boyd JH; Kan B; Roberts H; Wang Y; Walley KR
Circ Res; 2008 May; 102(10):1239-46. PubMed ID: 18403730
[TBL] [Abstract][Full Text] [Related]
40. TLR4 and RAGE conversely mediate pro-inflammatory S100A8/9-mediated inhibition of proliferation-linked signaling in myeloproliferative neoplasms.
Kovačić M; Mitrović-Ajtić O; Beleslin-Čokić B; Djikić D; Subotički T; Diklić M; Leković D; Gotić M; Mossuz P; Čokić VP
Cell Oncol (Dordr); 2018 Oct; 41(5):541-553. PubMed ID: 29946821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
